

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 150 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	ON NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/601,371	12/05/2000		Tsukasa Seya	49927 2244		
21874	7590 0	09/17/2003				
	S & ANGELL,	LLP	EXAMINER			
P.O. BOX 9 BOSTON, N				MERTZ, PREMA MARIA		
				ART UNIT	PAPER NUMBER	
				1646		
				DATE MAIL ED: 09/17/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Advisory Action	09/601,371	SEYA ET AL.	
Advisory Action	Examiner	Art Unit	
	Prema M Mertz	1646	1
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence add	ress
THE REPLY FILED FAILS TO PLACE THIS APP Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may <u>only</u> be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.) a timely filed amendment which	ation. A proper repl h places the applica	ation in
PERIOD FOR RE	EPLY [check either a) or b)]		
a) The period for reply expires 4 months from the mailing dat b) The period for reply expires on: (1) the mailing date of this no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Officinely filed, may reduce any earned patent term adjustment. See 37 (2)	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailing SFILED WITHIN TWO MONTHS OF The date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply ice later than three months after the mai	g date of the final rejecti HE FINAL REJECTION. R 1.136(a) and the appr unt of the fee. The appi originally set in the final	on. See MPEP opriate extension ropriate extension Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CF	R 1.191(d)), to avoid dismissal o		
2. The proposed amendment(s) will not be entered b	ecause:		
(a) X they raise new issues that would require furth	er consideration and/or search (s	see NOTE below);	
(b) they raise the issue of new matter (see Note be	•		
(c) they are not deemed to place the application i issues for appeal; and/or	n better form for appeal by mate	rially reducing or sir	nplifying the
(d) \square they present additional claims without cancel	ing a corresponding number of fi	nally rejected claim	s.
NOTE: <u>See Continuation Sheet</u> .			
3. Applicant's reply has overcome the following rejection	tion(s):		
 Newly proposed or amended claim(s) would canceling the non-allowable claim(s). 	be allowable if submitted in a se	eparate, timely filed	amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		dered but does NO	T place the
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were	e newly
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: <u>11-14</u> . Claim(s) withdrawn from consideration:			
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Exami	ner.
9. Note the attached Information Disclosure Stateme			
10. Other:			
		Prema M. Mertz Premary Examiner Art Unit: 1646	

Continuation Sheet (PTOL-303)

Application No. 09/601,371

Continuation of 2. NOTE: Claims 11-14 are drawn to M161Ag protein while new claims 15-17 are drawn to a method of treatment using the protein.